Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00870623 · ClinicalTrials.gov registry record
Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections
A clinical trial, sponsored by University of Nebraska.
- Completed
- Registry status
- 223
- Enrollment target
NCT00870623: Completed study, sponsored by University of Nebraska.
NCT00870623 is a clinical trial that has completed, run by University of Nebraska. The registered enrollment target is 223 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00870623 has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- 223 participants
- Enrollment target
Study Summary
Bloodstream infections (BSI) are a major cause of morbidity and mortality. Bloodstream infections are also costly and result in prolonged hospital stays. The duration of therapy necessary to clear blood stream infections is unknown and no study has systematically addressed this issue. However, the use of antimicrobials is not without consequence. These include financial cost, side-effects, promotion of superinfection (especially Clostridium difficile-associated diarrhea), and the promotion of microbial resistance. This study hypothesizes that a procalcitonin (host biomarker) and endotoxin (microorganism biomarker) guided treatment plan could significantly decrease unnecessary exposure to antibiotics in patients with bloodstream infections.
Primary Outcome
To determine the optimal length of treatment by observing the normalization of procalcitonin (PCT) and Endotoxin levels, compared with the length of treatment by standard of care.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2009-06-01 |
| Est. Completion | 2016-01-13 |
What the finished NCT00870623 record still lists
NCT00870623 is an observational study that tracks outcomes without assigning an intervention. The registered 223 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00870623 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00870623 about?
NCT00870623 is a clinical study titled "Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections". Bloodstream infections (BSI) are a major cause of morbidity and mortality. Bloodstream infections are also costly and result in prolonged hospital stays. The duration of therapy necessary to clear blood stream infections is unknown and no study has systematically addressed this issue. However, the u...
What is the current status of trial NCT00870623?
This trial is currently completed. The enrollment target is 223 participants. The study started on 2009-06-01. Estimated completion is 2016-01-13.
Who is sponsoring clinical trial NCT00870623?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06640803 · 223 participants · NA
Sacramento Clinical High Risk for Psychosis Stepped-Care Program
- NCT07175285 · 223 participants
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- NCT07205718 · 223 participants · Phase 1
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI